NASDAQ
PHIOW

Phio Pharmaceuticals Corp

Prices are adjusted according to historical splits.

Phio Pharmaceuticals Corp Stock Price

Vitals

Today's Low:
$0.0101
Today's High:
$0.0282
Open Price:
$0.0170
52W Low:
$0.011
52W High:
$0.73
Prev. Close:
$0.0170
Volume:
214336

Company Statistics

Market Cap.:
$0.003 billion
Book Value:
3.068
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-34.06%
Return on Equity TTM:
-63.97%

Company Profile

Phio Pharmaceuticals Corp had its IPO on 2016-12-21 under the ticker symbol PHIOW.

The company operates in the sector and industry. Phio Pharmaceuticals Corp has a staff strength of 11 employees.

Stock update

Shares of Phio Pharmaceuticals Corp opened at $0.02 at the start of the last trading session i.e. 2021-12-21.

The stocks traded within a range of $0.01 - $0.03, and closed at $0.02.

This is a +36.47% increase from the previous day's closing price.

A total volume of 214,336 shares were traded at the close of the day’s session.

In the last one week, shares of Phio Pharmaceuticals Corp have increased by 0%.

Phio Pharmaceuticals Corp's Key Ratios

Phio Pharmaceuticals Corp has a market cap of $0.003 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Phio Pharmaceuticals Corp’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.007 billion. The EBITDA ratio measures Phio Pharmaceuticals Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Phio Pharmaceuticals Corp’s operating margin was 0% while its return on assets stood at -34.06% with a return of equity of -63.97%.

In Q1, Phio Pharmaceuticals Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Phio Pharmaceuticals Corp’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
None

Its diluted EPS in the last 12-months stands at $-4.508 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Phio Pharmaceuticals Corp’s profitability.

Phio Pharmaceuticals Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Phio Pharmaceuticals Corp stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Phio Pharmaceuticals Corp ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Phio Pharmaceuticals Corp ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Phio Pharmaceuticals Corp’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Phio Pharmaceuticals Corp's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Phio Pharmaceuticals Corp paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$0.02
52-Week High
$0.73
52-Week Low
$0.011
Analyst Target Price
$None

Phio Pharmaceuticals Corp stock is currently trading at $0.02 per share. It touched a 52-week high of $0.73 and a 52-week low of $0.73. Analysts tracking the stock have a 12-month average target price of $None.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Phio Pharmaceuticals Corp

The stock symbol (also called stock or share ticker) of Phio Pharmaceuticals Corp is PHIOW

The IPO of Phio Pharmaceuticals Corp took place on 2016-12-21

Similar Industry Stocks ()

Last Price
Chg
Chg%
$27.63
-1.38
-4.76%
OP Bancorp (OPBK)
$11.24
0.09
+0.81%
$25.62
-1.05
-3.94%
$4.24
-0.1
-2.3%
Humana Inc (HUM)
$559.58
5.09
+0.92%
$1.35
-0.05
-3.57%
$4.91
-0.08
-1.6%
Paychex Inc (PAYX)
$114.5
-3.56
-3.02%
$12.62
-0.28
-2.17%
Evertec Inc (EVTC)
$33.95
-1.84
-5.14%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States. The company’s lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone for the clearance of common warts; and RXI-231, an sd-rxRNA compound targeting tyrosinase for use as a cosmetic ingredient that enhances the appearance of uneven skin tone and pigmentation. In addition, it develops RXI-109 that reduces the progression of retinal scarring. The company has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum Mnchen. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Address

257 Simarano Drive, Marlborough, MA, United States, 01752